WO2000061170A3 - Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid) - Google Patents

Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid) Download PDF

Info

Publication number
WO2000061170A3
WO2000061170A3 PCT/AT2000/000090 AT0000090W WO0061170A3 WO 2000061170 A3 WO2000061170 A3 WO 2000061170A3 AT 0000090 W AT0000090 W AT 0000090W WO 0061170 A3 WO0061170 A3 WO 0061170A3
Authority
WO
WIPO (PCT)
Prior art keywords
aag
orosomucoid
alpha
acidic glycoprotein
medical use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2000/000090
Other languages
English (en)
French (fr)
Other versions
WO2000061170A2 (de
Inventor
Konstantin Hiotakis
Herwig Ernst Reichl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemosan Erzeugung Pharmazeutischer Grundstoffe GmbH
HAEMOSAN ERZEUGUNG PHARMAZEUTI
Original Assignee
Haemosan Erzeugung Pharmazeutischer Grundstoffe GmbH
HAEMOSAN ERZEUGUNG PHARMAZEUTI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemosan Erzeugung Pharmazeutischer Grundstoffe GmbH, HAEMOSAN ERZEUGUNG PHARMAZEUTI filed Critical Haemosan Erzeugung Pharmazeutischer Grundstoffe GmbH
Priority to AU39453/00A priority Critical patent/AU3945300A/en
Priority to JP2000610502A priority patent/JP2002541209A/ja
Priority to EP00918560A priority patent/EP1171153A2/de
Priority to CA002369472A priority patent/CA2369472A1/en
Publication of WO2000061170A2 publication Critical patent/WO2000061170A2/de
Publication of WO2000061170A3 publication Critical patent/WO2000061170A3/de
Anticipated expiration legal-status Critical
Priority to US09/978,317 priority patent/US20020147137A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Beschrieben wird die Verwendung von α1-saurem Glykoprotein (AAG) zur Herstellung eines Arzneimittels zur Beeinflussung und Beschleunigung des Drogenentzuges, sowie ein Set, enthaltend α1-saures Glykoprotein und ein Plasmapherese-Set zum weiteren Plasmaaustausch mit Plasma und/oder Serumalbuminlösung.
PCT/AT2000/000090 1999-04-14 2000-04-14 Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid) Ceased WO2000061170A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU39453/00A AU3945300A (en) 1999-04-14 2000-04-14 Novel medical use of alpha1-acidic glycoprotein (aag) or orosomucoid
JP2000610502A JP2002541209A (ja) 1999-04-14 2000-04-14 α１酸性糖タンパク質（ＡＡＧ）又はオロソムコイドの新規な医学的使用
EP00918560A EP1171153A2 (de) 1999-04-14 2000-04-14 Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid)
CA002369472A CA2369472A1 (en) 1999-04-14 2000-04-14 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid)
US09/978,317 US20020147137A1 (en) 1999-04-14 2001-10-15 Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0066799A AT407485B (de) 1999-04-14 1999-04-14 Neue medizinische verwendung von alpha1-saurem glykoprotein
ATA667/99 1999-04-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/978,317 Continuation US20020147137A1 (en) 1999-04-14 2001-10-15 Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid

Publications (2)

Publication Number Publication Date
WO2000061170A2 WO2000061170A2 (de) 2000-10-19
WO2000061170A3 true WO2000061170A3 (de) 2001-05-10

Family

ID=3496646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2000/000090 Ceased WO2000061170A2 (de) 1999-04-14 2000-04-14 Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid)

Country Status (7)

Country Link
US (1) US20020147137A1 (de)
EP (1) EP1171153A2 (de)
JP (1) JP2002541209A (de)
AT (1) AT407485B (de)
AU (1) AU3945300A (de)
CA (1) CA2369472A1 (de)
WO (1) WO2000061170A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102578590B (zh) * 2011-01-06 2014-04-09 中国人民解放军第二军医大学 α1-酸性糖蛋白的应用
CN111157738A (zh) * 2019-12-28 2020-05-15 王贤俊 一种提高检测血清α1-酸性糖蛋白检测灵敏度的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0530173A2 (de) * 1991-08-19 1993-03-03 HÄMOSAN ERZEUGUNG PHARMAZEUTISCHER GRUNDSTOFFE GmbH Verfahren zur Inaktivierung von Prionen
WO1998040087A2 (de) * 1997-03-10 1998-09-17 Baxter Aktiengesellschaft VERWENDUNG VON HUMANEM α1-SAUREN GLYCOPROTEIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN PRÄPARATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604921D0 (en) * 1996-03-08 1996-05-08 Nat Blood Authority Purification method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0530173A2 (de) * 1991-08-19 1993-03-03 HÄMOSAN ERZEUGUNG PHARMAZEUTISCHER GRUNDSTOFFE GmbH Verfahren zur Inaktivierung von Prionen
WO1998040087A2 (de) * 1997-03-10 1998-09-17 Baxter Aktiengesellschaft VERWENDUNG VON HUMANEM α1-SAUREN GLYCOPROTEIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN PRÄPARATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARRIDO M J ET AL: "Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal.", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 48, no. 3, 1996, pages 281 - 284, XP000953120, ISSN: 0022-3573 *

Also Published As

Publication number Publication date
WO2000061170A2 (de) 2000-10-19
ATA66799A (de) 2000-08-15
JP2002541209A (ja) 2002-12-03
CA2369472A1 (en) 2000-10-19
AT407485B (de) 2001-03-26
EP1171153A2 (de) 2002-01-16
AU3945300A (en) 2000-11-14
US20020147137A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2002227332A1 (en) Hemodiafiltration / hemofiltration cartridges
EP1340815A3 (de) Bestimmung von alpha-N-acetylgalactosaminidase Aktivität
WO2001045712A8 (de) Arzneimittelkombinationen gegen virale erkrankungen
AU4716299A (en) Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
AU2002355230A1 (en) Blood dialyzer
ITFI920078A0 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umana.
EP1386612A4 (de) Arzneimittel zur förderung von proliferation, differenzierung und/oder überleben von gliazellen, die cyclische phosphatidsäure enthalten
AUPP971399A0 (en) Separation of plasma components
AU6926496A (en) New cyclic guanidines, process for preparing the same and medicaments
AU2002354009A1 (en) Process for the preparation of secondary and tertiary amino-functional silanes, iminoorganosilanes and/or imidoorganosilanes
EP0420765A3 (en) Blood plasma-separating membrane and blood plasma separator using the membrane
WO2000061170A3 (de) Neue medizinische verwendung von alpha-1-saurem glykoprotein (aag oder orosomucoid)
AU2001238194A1 (en) Blood serum or plasma stabilization system
AU5677700A (en) Method for the enantiomer separation of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane
AU2001232053A1 (en) System for the extracorporeal treatment of blood
CA2285463A1 (en) A combination therapy for hiv infections
WO1996001110A3 (en) Anti-hiv triple combination
AU4145999A (en) Topical drug for the treatment of viral infections
WO2001087229A3 (en) Treating infections
AU2505701A (en) Communication system for the interaction between medical laboratories and medical treatment centers
AU7464194A (en) Process for the preparation of cumene hydroperoxide
MXPA02001479A (es) Solucion de reemplazo de plasma sanguineo.
AU1673200A (en) Medicaments for the treatment of lung infections
AU4500299A (en) Use of a medicine containing a quantity of tyrothricine for the treatment of viral infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610502

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 39453/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2369472

Country of ref document: CA

Ref country code: CA

Ref document number: 2369472

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09978317

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000918560

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000918560

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000918560

Country of ref document: EP